Trans-NIH cannabis consortium

Part A of title IV of the Public Health Service Act (42 U.S.C. 281 et seq.) is amended by inserting at the end the following: 404P. Trans-NIH cannabis consortium (a) Establishment The Director of NIH shall establish and maintain a consortium to be known as the Trans-NIH Cannabis Research Consortium (referred to in this section as the Consortium) to coordinate cannabis research programs across the National Institutes of Health. (b) Membership The members of the Consortium shall be appointed by the Director of NIH and consist of representatives of multiple national research institutes and national centers. (c) Chair The Chair of the Consortium shall be the Director of the National Institute on Drug Abuse (or the Director’s designee). (d) Duties In coordinating cannabis research programs across the National Institutes of Health, the Consortium shall— (1) establish cannabis research priorities; (2) identify gaps and opportunities for research collaborations involving multiple national research institutes and national centers; and (3) identify opportunities to develop the next generation of cannabis researchers. (e) Consultation The Consortium shall consult regularly with external experts in the field of cannabis research, as appropriate, including industry, patient organizations, and other stakeholders. (f) Reporting No later than 1 year after the date of enactment of the Cannabis Administration and Opportunity Act, and every 2 years thereafter, the Consortium shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, and make publicly available on the website of the National Institutes of Health, a report on— (1) any research project involving cannabis and involving more than one national research institute or national center that was supported during the review period; (2) any strategic initiatives that include a significant component related to cannabis; (3) career development awards for early-career researchers focused in cannabis research, including specific numbers of awards and amount of funding, made during the review period; (4) details on the composition of awards for early-career researchers, including demographic details indicating the proportion of recipients from populations that have been underrepresented in cannabis research; and (5) such other information as the Director of NIH determines appropriate..